




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 38/00, 47/30, 47/32, 47/42, C07K 16/00, 17/00, 17/14, C08F 110/02, 110/04, C12P 21/00, 21/08</p>	<p>A1</p>	<p>(11) International Publication Number: WO 96/00080</p> <p>(43) International Publication Date: 4 January 1996 (04.01.96)</p>
<p>(21) International Application Number: PCT/US95/08909</p> <p>(22) International Filing Date: 23 June 1995 (23.06.95)</p> <p>(30) Priority Data: 08/265,593 24 June 1994 (24.06.94) US</p> <p>(71) Applicant: ENZON, INC. [US/US]; 20 Kingsbridge Road, Piscataway, NJ 08854 (US).</p> <p>(72) Inventors: GREENWALD, Richard, B.; 113 Hickory Road, Somerset, NJ 08873 (US). MARTINEZ, Anthony; 20 Weyburne Road, Hamilton Square, NJ 08690 (US). PENDRI, Annapurna; 108 Winston Drive, Matawan, NJ 07747 (US).</p> <p>(74) Agents: MERCANTI, Michael, M. et al.; Steinberg, Raskin & Davidson, P.C., 1140 Avenue of the Americas, New York, NY 10036 (US).</p>	<p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).</p> <p>Published <i>With international search report.</i></p>	

(54) Title: NON-ANTIGENIC AMINE DERIVED POLYMERS AND POLYMER CONJUGATES



(57) Abstract

Substantially non-antigenic polymers containing pI and/or pH optimum modulating moieties are disclosed. The polymers are useful as intermediates for synthesis of amine-based polymers and in the formation of activated polymers for conjugation with nucleophiles. Conjugates and methods of preparation and treatment with the conjugates are also disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**NON-ANTIGENIC AMINE DERIVED POLYMERS
AND POLYMER CONJUGATES**

Cross-reference to related applications

This application is a continuation-in-part of U.S. Patent Application Serial No. 08/ 265,593 filed June 24, 1994.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to polymers which are useful in extending the in vivo circulating life of biologically active materials. The invention also relates to conjugates made with the polymers.

2. Description of Prior Art

Some of the initial concepts of coupling peptides or polypeptides to poly(ethylene glycol) PEG and similar water-soluble poly(alkylene oxides) are disclosed in U.S. Patent No. 4,179,337, the disclosure of which is incorporated herein by reference. Polypeptides modified with these polymers exhibit reduced immunogenicity or antigenicity and circulate in the bloodstream longer than unmodified versions.

To conjugate poly(alkylene oxides), one of the hydroxyl end-groups is converted into a reactive functional group. This process is frequently referred to as "activation" and the product is called an "activated poly(alkylene oxide)". Other substantially non-antigenic polymers are similarly "activated" or functionalized.

The activated polymers are reacted with a therapeutic agent having nucleophilic functional group(s) that serve as attachment site(s). One nucleophilic

functional group commonly used as an attachment site is the epsilon-amino group of lysines. Free carboxylic acid groups, suitably activated carbonyl groups, oxidized carbohydrate moieties, hydroxyl and mercapto groups have also been used as attachment sites.

Over the years, one shortcoming observed with polymer conjugation is that the conjugate has a different pI than the unmodified protein, enzyme, etc. For example, pegylation, i.e. attachment of the polymer, of lysine amino groups result in a decrease in the isoelectric point and changes the pH optimum, i.e. the pH at which maximum bioactivity is observed. In some cases, it would be beneficial to restore the original pI or even alter the pI value of the polymer conjugate in order to optimize bioactivity at physiologic pH.


The present invention provides solutions to this problem.

SUMMARY OF THE INVENTION

In one aspect of the invention, there are provided amine-based polymer intermediates having the formula:



wherein (R) is a water-soluble, substantially non-antigenic polymer residue and (B) is preferably a secondary amine or a tertiary amine. Suitable secondary amines are of the formula:




wherein:

(n) is an integer from 1-12, inclusive; and


X is selected from the group consisting of H; OH; CO₂R₁, where R₁ is H or a C₁₋₆ alkyl; halogen, aryl moieties and heteroaromatic moieties.

Suitable tertiary amines can be selected from:




3

(IV)




5

(V)



10

(VI)



15

wherein (m) is an integer from 0-12, inclusive;

20

(X) is selected from the group consisting of H, OH, CO₂R₁, where R₁ is H or a C₁₋₆ alkyl, halogen, aryl moieties and heteroaromatic moieties;

(Y) is N or CH; and

(Z) is a C₁₋₆ alkyl.

25


The polymer is preferably a poly(alkylene oxide) residue such as a poly(ethylene glycol) having a molecular weight between about 200 and about 100,000. In addition, the polymer is preferably capped with a C₁₋₄ alkyl group on the end opposite (i.e. distal to) the B moiety.

In another aspect of the invention, there are provided substantially non-antigenic polymers of the formula:

(VII) R-B'-W-L

wherein (R) is as defined above; (B') is NY, where Y is H or a C₁₋₆ alkyl or cycloalkyl; (W) is a spacer group, such as a C₁₋₆ alkyl and (L) is a functional group capable of bonding with nucleophiles.

Other aspects of the invention include polymer conjugates containing biologically-active materials, described as nucleophiles herein as well as methods of conjugate preparation. In these aspects of the invention, the conjugates are of the formula:



wherein:

(R), (B') and (W) are as described above;

(L¹) represents a covalent linkage between (R-B'-W) and a nucleophile; and

(z) represents the number of polymers attached to the nucleophile.

The biologically active materials include proteins, peptides, enzymes, medicinal chemicals or organic moieties whether synthesized or isolated from nature. The conjugation methods include contacting a nucleophile, i.e. a biologically active material, capable of undergoing a substitution reaction with a polymer described. The reaction is carried out under conditions sufficient to effect attachment while maintaining at least a portion of the biological activity.

The present invention also includes methods of treating various maladies and conditions. In this aspect, a mammal in need of treatment is administered an effective amount of a conjugate containing a biologically-active material such as a protein, enzyme or organic moiety attached to a polymer of the present invention.

Some of the chief advantages of the present invention are that the amine-derived polymers impart a pI and/or pH modulating effect to the conjugate. Thus, the isoelectric point of bio-active materials included in the conjugate can be adjusted to a desired point. This is to be contrasted with the effect observed with conventional activated polymers where shifts in isoelectric points can be observed, often to the detriment of optimal activity.

In addition, in those aspects of the invention where anionic groups are included as part of the amine-bearing moiety, the *in vivo* circulating life of the conjugates is further prolonged due to reduced renal filtration.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic representation of synthesis techniques carried out in accordance with the invention to prepare formula (I) R-B polymer intermediates and the compounds of Examples 1 and 3-6.

Figure 2 is a schematic representation of synthesis techniques carried out in accordance with the invention to prepare the compounds described in Examples 2 and 7-9.

Figure 3 is a schematic representation of the reactions carried out in Examples 10-11

Figure 4 is a schematic representation of the reactions carried out in Examples 12-16.

DETAILED DESCRIPTION OF THE INVENTION

1. POLYMER RESIDUES

The activated polymers of the present invention are preferably prepared from poly(alkylene oxides) (PAO's) that are water soluble at room temperatures. Within this group are mono-substituted polyalkylene oxide derivatives such as methoxypoly(ethylene glycols) (mPEG's) or other suitable alkyl-substituted PAO derivatives such as those containing a C₁ - C₄ terminal group. Straight-chained non-antigenic polymers such as monomethyl PEG homopolymers are preferred. Alternative polyalkylene oxides such as other poly(ethylene glycol) homopolymers, polypropylene glycols, other alkyl-poly(ethylene oxide) block copolymers, and copolymers of block copolymers of poly(alkylene oxides) are also useful. Branched PAO's such as those disclosed in commonly-assigned the PCT International Application having International Publication No. WO95/ 11924 are also of use herein. The disclosure of WO95/11924 is hereby

incorporated by reference herein.

Alternative polymer substances useful herein include materials such as dextrans, polyvinyl pyrrolidones, polyacrylamides or other similar non-immunogenic polymers. Those of ordinary skill in the art will appreciate that these polymers can also be functionalized and included in the invention. The foregoing is merely illustrative and not intended to restrict the type of non-antigenic polymers suitable for use herein.

Thus, (R) is a water-soluble, substantially non-antigenic polymer residue. When the (R) is PEG or mPEG, molecular weights of between about 200 and about 100,000 daltons are preferred; molecular weights of about 1,000 - 50,000 daltons are more preferred and molecular weights of about 2,500 - 25,000 daltons are most preferred.

2. AMINE PORTION OF ACTIVATED POLYMER

In one aspect of the invention, amine-based polymer intermediates are provided. The amine portion of the intermediates can be a secondary, tertiary or quaternary amine moiety, represented herein as (B) in formula (I). Preferably, however, either secondary or tertiary amines are used.

When a secondary amine is selected for (B), amines of the formula (II) are preferred:



wherein


(n) is an integer from 1-12, inclusive; and

(X) is selected from the group consisting of H; OH; CO₂R₁, where R₁ is H or a C₁₋₆ alkyl; halogen; aryl moieties and heteroaromatic moieties.

These secondary amine moieties can be synthesized using standard organic techniques or can be readily obtained using reagents available from commercial sources. A non-limiting list of secondary amines meeting these criteria include: primary amines such as ethanolamine, beta-alanine ethyl ester,

paramethoxybenzylamine, etc.

When a tertiary amine is desired for (B), amines of formulae (III-VI) are preferred:



wherein

25 (m) is an integer from 0-12, inclusive;

(X) is selected from the group consisting of H; OH; CO₂R₁, where R₁ is H or a C₁₋₆ alkyl; halogen, aryl moieties and heteroaromatic moieties;

(Y) is N or CH; and

(Z) is a C₁₋₆ alkyl.

The tertiary amine moieties can be synthesized using standard organic techniques or can be readily obtained from commercial sources. A non-limiting list of tertiary amines meeting these criteria include secondary amines such as N-methylethanolamine, piperidine-3-methanol, N-hydroxypropylpiperazine, sarcosine ethyl ester, etc.

3. SYNTHESIS OF POLYMERS INTERMEDIATES

The polymer intermediates of formula (I) can be synthesized using conventional reaction techniques. For example, mPEG-Cl can be reacted with ethanolamine available from Aldrich or any other suitable primary amine in water and a sealed container at temperatures of approximately 60° C to form secondary amine polymer intermediates.

Similarly, mPEG-Cl can be reacted with secondary amines such as N-methylethanolamine under similar conditions to form tertiary amine polymer intermediates.

In still other aspects of the invention, the amine-bearing groups (B) can also include an acid moiety, preferably as part of the alkyl portion thereof. A non-limiting list of suitable acids include sulfonates, carboxylates and phosphonates. As demonstrated in Examples 12-16, a trifunctional spacer moiety such as lysine or serine is first reacted with an activated polymer such as a PEG-succinimidyl succinate ester or a PEG-succinimidyl carbonate. Next, an anion group is added by modifying one of the remaining functional groups on the (B) portion of the intermediate. Reagents such as chloroethane sulfonic acid sodium salt, phosphonic acid esters or salts or ethylbromoacetate can be used. (Ethylbromoacetate first forms a carboxylate ester and then can be saponified to a salt.) Finally, the third functional group of (B) can be modified with a leaving group (L) described below in section 4.

The foregoing is merely illustrative of syntheses useful to prepare the intermediates. It is to be understood that alternative methods and reagents may be used without departing from the spirit of the invention. In essence, each (R) and (B)

is joined by a reaction between nucleophilic functional groups. Each (R) is suitably functionalized, i.e. mPEG-halides such as mPEG-Cl; PEG sulfonate esters such as PEG-tosylate, etc. to undergo nucleophilic substitution and bond with (B). Functionalization of polymers with halides or sulfonate esters is readily apparent to those of ordinary skill in the art.

4. ACTIVATED AMINE-BASED POLYMERS

In yet another aspect of the invention, the intermediates described above are included as part of activated polymers which can be used to conjugate with biologically-active nucleophiles. The polymers have the formula:



wherein

(R) is a water-soluble, substantially non-antigenic polymer residue;

(B') is NY, wherein Y is H or a C₁₋₆ alkyl or cycloalkyl;

(W) is a spacer group; and

(L) is a functional group capable of bonding with nucleophiles.

The (R-B') portion of the polymer can be prepared as described above with regard to (R-B).

The moiety (W) of Formula (VII) represents a spacer group between the (R-B') and the leaving group (L). It has been found that straight or branched lower alkyls i.e. C₁₋₄, aralkyl, aryl or heteroaryl groups may be employed. In this regard, alternative (W) substituents include benzyl, substituted benzyls, phenylethyl, substituted phenylethyls, phenyl, substituted phenyls, thiophene derivatives, pyridine derivatives, hydroxyaniline, etc. The foregoing list of (W) substituents is to be understood as being illustrative of suitable moieties and not an exclusive list. Those of ordinary skill will realize that functional equivalents of the foregoing are also possible for (W).

The spacer adjusts the geometry of the system in order to prevent undesirable side reactions, thus increasing the yield of the desired polymer-nucleophile conjugate.

Preferred spacer groups (W) include:

1. ethyl-3-isocyanato propionate; and
2. ethyl-2-aminobutyrate.

The spacer groups are available from commercial sources or can be synthesized using standard laboratory techniques.

Furthermore, the spacer groups can be attached to the (R-B) portion of the polymer by simple nucleophilic or electrophilic substitution reactions.

The moiety (L) of Formula (VII) represents leaving groups that "activate" the amine-based polymers of the present invention for conjugation with nucleophiles.

(L) can be a moiety selected from:

- I. Functional groups capable of reacting with an amino group such as:
 - a) carbonates such as the p-nitrophenyl, or succinimidyl;
 - b) carbonyl imidazole;
 - c) azlactones;
 - d) cyclic imide thiones;
 - e) isocyanates or isothiocyanates; or
 - f) other active esters.
- II. Functional groups capable of reacting with carboxylic acid groups and reactive carbonyl groups such as:
 - a) primary amines; or
 - b) hydrazine and hydrazide functional groups such as acyl hydrazides, carbazates, semicarbazates, thiocarbazates, etc.
- III. Functional groups capable of reacting with mercapto groups such as unsaturated maleimides.

5. SYNTHESIS OF ACTIVATED AMINE-BASED POLYMERS

The activated polymers are formed using conventional reaction techniques. For example, an alcohol form of the intermediate (R-B), formula (I), or the intermediate (R-B'-W) of formula (VII) can be reacted with N-hydroxysuccinimide and diisopropylcarbodiimide, both available from Aldrich, in dry methylene chloride

at a temperature of about 25° C. Other inert organic solvents such as toluene, THF, etc can be used and temperatures ranging from 1-100 ° C can be employed. Synthesis reactions are schematically shown in Figures 1-4 for both secondary and tertiary amine-containing activated polymers.

5 6. **BIOLOGICALLY ACTIVE MATERIALS SUITABLE FOR CONJUGATION**

10 The nucleophiles conjugated with the polymers are described as "biologically active". The term, however, is not limited to physiological or pharmacological activities. For example, some nucleophile conjugates such as those containing enzymes, are able to catalyze reactions in organic solvents. Likewise, some inventive polymer conjugates containing proteins such as concanavalin A, immunoglobulin and the like are also useful as laboratory diagnostics. A key feature of all of the conjugates is that at least some portion of the activity associated with the unmodified bio-active material is maintained.

15 In other aspects of the invention, the conjugates are biologically active and have numerous therapeutic applications. Mammals in need of treatment which includes a biologically active material can be treated by administering an effective amount of a polymer conjugate containing the desired bioactive material. For example, mammals in need of enzyme replacement therapy or blood factors can be given polymer conjugates containing the desired material. The therapeutically effective doses of the conjugates will be apparent to those of ordinary skill in the invention. It is contemplated, however, that the doses will be calculated of the basis of the biologically active material present in the conjugates.

20 Biologically active nucleophiles of interest of the present invention include, but are not limited to, proteins, peptides, polypeptides, enzymes, organic molecules of natural and synthetic origin such as medicinal chemicals and the like.

25 Enzymes of interest include carbohydrate-specific enzymes, proteolytic enzymes, oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases. Without being limited to particular enzymes, examples of enzymes of interest include

30

asparaginase, arginase, arginine deaminase, adenosine deaminase, superoxide dismutase, endotoxinases, catalases, chymotrypsin, lipases, uricases, adenosine diphosphatase, tyrosinases and bilirubin oxidase. Carbohydrate-specific enzymes of interest include glucose oxidases, glucodases, galactosidases, glucocerebrosidases, glucouronidases, etc.

Proteins, polypeptides and peptides of interest include, but are not limited to, hemoglobin, serum proteins such as blood factors including Factors VII, VIII, and IX; immunoglobulins, cytokines such as interleukins, α -, β - and γ -interferons, colony stimulating factors including granulocyte colony stimulating factors, platelet derived growth factors and phospholipase-activating protein (PLAP). Other proteins of general biological or therapeutic interest include insulin, plant proteins such as lectins and ricins, tumor necrosis factors and related alleles, growth factors such as tissue growth factors, such as TGF α 's or TGF β 's and epidermal growth factors, hormones, somatomedins, erythropoietin, pigmentary hormones, hypothalamic releasing factors, antidiuretic hormones, prolactin, chorionic gonadotropin, follicle-stimulating hormone, thyroid-stimulating hormone, tissue plasminogen activator, and the like. Immunoglobulins of interest include IgG, IgE, IgM, IgA, IgD and fragments thereof.

Some proteins such as the interleukins, interferons and colony stimulating factors also exist in non-glycosylated form, usually as a result of using recombinant techniques. The non-glycosylated versions are also among the biologically active nucleophiles of the present invention.

The biologically active nucleophiles of the present invention also include any portion of a polypeptide demonstrating *in vivo* bioactivity. This includes amino acid sequences, antisense moieties and the like, antibody fragments, single chain binding antigens, see, for example U.S. Patent No. 4,946,778, disclosure of which is incorporated herein by reference, binding molecules including fusions of antibodies or fragments, polyclonal antibodies, monoclonal antibodies, catalytic antibodies, nucleotides and oligonucleotides.

The proteins or portions thereof can be prepared or isolated by using


techniques known to those of ordinary skill in the art such as tissue culture, extraction from animal sources, or by recombinant DNA methodologies. Transgenic sources of the proteins, polypeptides, amino acid sequences and the like are also contemplated. Such materials are obtained from transgenic animals, i.e., mice, pigs, cows, etc., wherein the proteins expressed in milk, blood or tissues. Transgenic insects and baculovirus expression systems are also contemplated as sources. Moreover, mutant versions of proteins, such as mutant TNF's and/or mutant interferons are also within the scope of the invention.

Other proteins of interest are allergen proteins such as ragweed, Antigen E, honeybee venom, mite allergen, and the like. However, useful biologically active nucleophiles are not limited to proteins and peptides. Essentially any biologically-active compound is included within the scope of the present invention. Chemotherapeutic molecules such as pharmaceutical chemicals i.e. anti-tumor agents such as taxol, taxanes, camptothecin, anthracyclines, methotrexate, etc., cardiovascular agents, anti-neoplastics, anti-infectives, anti-anxiety agents, gastrointestinal agents, central nervous system-activating agents, analgesics, fertility or contraceptive agents, anti-inflammatory agents, steroidal agents, anti-uricemic agents, cardiovascular agents, vasodilating agents, vasoconstricting agents and the like can all be conjugated with the amine-bearing polymers of the present invention.

The foregoing is illustrative of the biologically active nucleophiles which are suitable for conjugation with the polymers of the invention. It is to be understood that those biologically active materials not specifically mentioned but having suitable nucleophilic groups are also intended and are within the scope of the present invention.

7. SYNTHESIS OF BIOLOGICALLY ACTIVE CONJUGATES

One or more of the activated polymers can be attached to a biologically active nucleophile by standard chemical reactions. The conjugate is represented by the formula:



wherein:

(R) is a water-soluble substantially non-antigenic polymer residue;

(B') is NY, wherein Y is H or a C₁₋₆ alkyl or cycloalkyl;

(W) is a spacer moiety;

(L¹) represents a covalent linkage between (R-B'-W) and the nucleophile; and

(z) Represents the number of polymers attached to the nucleophile.

The variable (z) is an integer ≥ 1 representing the number of polymers conjugated to the biologically active nucleophile. The upper limit for (z) will be determined by the number of available nucleophilic attachment sites and the degree of polymer attachment sought by the artisan. The degree of conjugation can be modified by varying the reaction stoichiometry using well-known techniques. More than one polymer conjugated to the nucleophile can be obtained by reacting a stoichiometric excess of the activated polymer with the nucleophile.

The biologically active nucleophiles can be reacted with the activated polymers in an aqueous reaction medium which can be buffered, depending upon the pH requirements of the nucleophile. The optimum pH for the reaction is generally between about 6.5 and about 8.0 and preferably about 7.4 for proteinaceous/polypeptide materials. Organic/chemotherapeutic moieties can be reacted in non-aqueous systems. The optimum reaction conditions for the nucleophile's stability, reaction efficiency, etc. is within level of ordinary skill in the art. The preferred temperature range is between 4°C and 37°C. The temperature of the reaction medium cannot exceed the temperature at which the nucleophile may denature or decompose. It is preferred that the nucleophile be reacted with an excess of the activated polymer. Following the reaction, the conjugate is recovered and purified such as by diafiltration, column chromatography, combinations thereof, or the like.

It can be readily appreciated that the activated non-antigenic polymers of the present invention are a new and useful tool in the conjugation of biologically active materials, especially when shifts in pI and/or pH optimum are sought.

EXAMPLES

The following non-limiting examples illustrate certain aspects of the invention. All parts and percentages are by weight unless otherwise noted and all temperatures are in degrees Celsius. The numbers associated with all compositions in the examples correspond to those shown in the figures.

MATERIALS

Methoxypoly(ethylene glycol) (m-PEG) having a molecular weight of about 5,000 was obtained from Union Carbide. All polyethylene glycols were molecular weight 5,000 unless stated otherwise. The solvents were obtained from Aldrich Chemical of Milwaukee, Wisconsin. Each of the products prepared was confirmed structurally by carbon - 13 NMR.

EXAMPLE 1

m-PEG-Cl :

A total of 1 kg (0.2 moles) of m-PEG-OH was placed under high vacuum and heated to 70° C with stirring until the evolution of gas (H₂O) ceased after approximately 4 hours. The temperature was lowered to 50° C, followed by the addition of 100 ml (1.4 moles) of thionyl chloride. This mixture was stirred overnight at 70° C under nitrogen, cooled to 30° C, and titrated with ethyl ether to yield 990 g (99% yield) of product. ¹³C NMR: (CDCl₃)δ; CH₂Cl, 42.3.

EXAMPLE 2

m-PEG Piperidinemethanol (7):

A mixture of 25.0 g (5.0 mmoles) of m-PEG-Cl and 5.75 g (50 mmoles) of 3-piperidinemethanol (6) in 100 ml of water was placed in a 250 ml polypropylene bottle. The bottle was sealed and kept in a water bath at 60° C for 48 hours followed by cooling to room temperature and removal of the solvent by distillation in vacuo. Recrystallization of the residue from 2-propanol yielded of product (7). ¹³C NMR: (CDCl₃)δ; CH₂ (ring), 23.94, 26.47; CHCH₂OH, 37.56; CH₂N, 53.91, 56.96, 57.38; CH₃O, 57.93; CH₂OH, 65.05.

EXAMPLE 3**m-PEG Piperazinepropanol (2):**

A mixture of 25.0 g (5.0 mmoles) of m-PEG-Cl and 7.2 g (50 mmoles) of N-hydroxypropylpiperazine (1) in 100 ml of water was placed in a 250 ml polypropylene bottle. The bottle was sealed and kept in a water bath at 60° C for 48 hours followed by cooling to room temperature and removal of the solvent by distillation in vacuo. Recrystallization of the residue from 2-propanol yielded 24.5 g (96% yield) of product (2). ¹³C NMR: (CDCl₃) δ; CH₂CH₂OH, 26.85; CH₂N (endocyclic), 52.19, 52.48; CH₂N (exocyclic), 56.66, 56.81; CH₃O, 57.90; CH₂OH, 62.18.

EXAMPLE 4**SYNTHESIS OF COMPOUND (3a)**

mPEG-piperazine propanol (2), (16 g, 3.1 mmol) in toluene (240 ml) was azeotroped for 2 hours, followed by the removal of 100 ml toluene. Thereafter, ethyl-3-isocyanatopropionate (1.34 g, 9.36 mmol) and dibutyl tin dilaurate (0.99 g, 1.56 mmol) were added to this solution at room temperature. The resulting mixture was heated to 60°C for 30 hours. The solvent was removed under reduced pressure and the solid obtained was recrystallized from 2-propanol to give (3a) in 96% yield. ¹³C NMR: (CDCl₃) δ; 13.43 (OCH₂CH₃); 25.40 (CH₂CH₂CH₂); 33.63 (CH₂C); 35.73 (CNCH₂); 51.56, 52.19 (CH₂N endocyclic); 53.92, 56.61 (CH₂N exocyclic); 58.11 (OCH₃); 59-60 (OCH₂CH₃); 62.01 (CH₂OC); 155.62 (OCN); 171.14 (COC₂H₅).

EXAMPLE 5**SYNTHESIS OF COMPOUND (3b)**

Compound (3a) (15 g, 2.9 mmol) was dissolved in H₂O (200 ml) followed by the addition of lithium hydroxide (733 mg, 125 mmol). The solution was stirred for 18 hours and pH was adjusted to 4.0 using 6N HCl. The aqueous solution was extracted with methylene chloride and the solvent was removed in vacuo. The solid obtained was recrystallized from CH₂Cl₂/ether to give (3b) in 96.6% yield. ¹³C NMR: (CDCl₃) δ; 24.21 (CH₂CH₂CH₂); 33.49 (CH₂C); 35.94 (NHCH₂); 49.71, 50.52 (CH₂N endocyclic); 53.29, 55.79 (CH₂N exocyclic); 58.12 (OCH₃); 61.19 (CH₂OC); 155.49

(OCN); 172.96 (COH).

EXAMPLE 6

A. SYNTHESIS OF COMPOUND (4)

Compound 3b (14 g, 2.71 mmol) was dissolved in anhydrous methylene chloride (70 ml) followed by the addition of N-hydroxysuccinimide (619 mg; 5.4 mmol) and 1,3-diisopropyl carbodiimide (683 mg, 5.42 mmol). The mixture was stirred overnight at room temperature. The resulting solids were filtered and the solvent was removed under reduced pressure. The crude product was recrystallized from 2-propanol to give compound (4) in 94% yield. ¹³C NMR: (CDCl₃) δ; 24.84 (CH₂CH₂CH₂CH₂, succinimide); 30.94 (CH₂C); 35.74 (NCH₂); 49.84, 49.98, 50.05, 50.74 (CH₂N endocyclic); 53.29, 55.90 (CH₂N exocyclic); 58.15 (OCH₃); 61.48 (CH₂OC); 155.56 (CN); 166.51 (CH₂CO); 168.73 (C succinimide).

B. SYNTHESIS OF COMPOUND (5) BY CONJUGATION OF COMPOUND (4) WITH BENZYLAMINE

Benzylamine (9 μl) was added to the solution of compound (4) (0.4 g) in CDCl₃ in the NMR tube. Resulting solids were dissolved by gentle heating and tapping and left at room temperature for 18 hours. ¹³C NMR of the resulting solution indicates the formation of product. Thus, it is shown that the amine-based polymers of the present invention react readily with nucleophiles to form conjugates. ¹³C NMR: (CDCl₃) δ; 24.67 (CH₂CH₂CH₂); 24.58 (CH₂ free succinimide); 34.87 (CH₂C); 36.50 (HNCH₂); 42.31, 42.81 (CH₂ benzyl); 50.76, 51.18 (CH₂N endocyclic); 53.58, 56.16 (CH₂N); 58.12 (CH₃O); 61.50 (CH₂OC); 126.77 to 138.11 (C Benzene ring); 155.67 (CN); 170.77 (CH₂CON); 172.55 (CO free succinimide).

EXAMPLE 7

SYNTHESIS OF COMPOUND (8a)

mPEG-piperidine methanol (7) (5 g, 1 mmol) in toluene (75 ml) was azeotroped for 2 hours, followed by the removal of 30 ml toluene. To this solution ethyl-3-isocyanate propionate (421 mg, 2.9 mmol) and dibutyl tin dilaurate (310 mg, 0.49 mmol) were added at room temperature were added and the resulting mixture was

heated to 60°C for 30 hours. The solvent was removed under reduced pressure and the solid obtained was recrystallized from 2-propanol to give (8a) in 91% yield. ¹³C NMR: (CDCl₃) δ; 13.30 (OCH₂CH₃); 23.32 (CH₂ ring); 33.47 (CH₂C); 35.65 (NCH₂); 34.75 (CH₂ ring); 53.37, 56.32 (CH₂N); 57.94, (OCH₃); 59.42 (OCH₂CH₃); 66.17 (CH₂OC); 155.49 (CN); 170.92 (CH₂CO).

EXAMPLE 8

SYNTHESIS OF COMPOUND (8b)

Compound (8a), (4.5 g, 0.86 mmol) was dissolved in H₂O (60 ml) followed by the addition of lithium hydroxide (216 mg, 5.15 mmol). The solution was stirred for 18 hours and pH was adjusted to 4.0 using 6N HCl. The aqueous solution was extracted with CH₂Cl₂ and the solvent was removed under reduced pressure. The solid obtained was recrystallized from CH₂Cl₂/ether mixture to give (8b) in 98% yield. ¹³C NMR: (CDCl₃) δ; 21.23, 24.19 (CH₂ ring); 32.95 (CH₂C); 133.88 (CH ring); 36.12 (NCH₂); 57.99, (OCH₃); 64.90 (CH₂OC); 155.27 (OCN); 173.56 (C-OH).

EXAMPLE 9

A. SYNTHESIS OF COMPOUND (9)

Compound (8b) (2 g, 0.38 mmol) was dissolved in anhydrous methylene chloride (10 ml) followed by the addition of N-hydroxysuccinimide (88.3 mg, 0.77 mmol) and 1,3-diisopropylcarbodiimide (96.7 mg, 0.77 mmol). The mixture was stirred overnight at room temperature. The resulting solids were filtered and the solvent was removed under reduced pressure. The crude product was recrystallized from 2-propanol to give compound (9) in 88% yield. ¹³C NMR: (CDCl₃) δ; 21.67, 24.65 (CH₂ ring); 24.50 (CH₂ succinimide); 30.62 (CH₂C); 33.36 (CH ring); 35.58 (NCH₂); 52.64, 54.98, 55.06 (CH₂N); 57.94 (OCH₃); 155.32 (OCN); 166.31 (CH₂CO); 168.60 (succinimide).

B. SYNTHESIS OF COMPOUND (10) BY CONJUGATION WITH COMPOUND (9) WITH BENZYLAMINE

Benzylamine (9.1 μl) was added to the solution of compound (9) (0.4 g) in CDCl₃ in the NMR tube. Resulting solids were dissolved by gentle heating and tapping

and left at room temperature for 18 hours. ^{13}C NMR of the resulting solution indicates the formation of product (10). ^{13}C NMR: (CDCl_3) δ ; 21.80, 21.49 (CH_2 ring); 24.39 (CH_2 , succinimide); 33.44 (CH_2C); 36.39 (CH_2N); 34.72 (CH ring); 42.08, 42.65 (CH_2 benzylamine); 52.51, 55.07, 55.98 (CH_2N); 57.91 (OCH_3); 126.06 to 138.03 (C Benzene ring); 155.53 (OCN); 170.56 (CH_2CN); 172.31 (C succinimide).

EXAMPLE 10

SYNTHESIS OF N-PEG SARCOSINE (12)

mPEG-Cl (25 g, 4.98 mmol) was added to the solution of N-methyl glycine (sarcosine) (11) in NaOH solution (150 ml, 0.33 M) and the mixture was placed in a sealed polypropylene bottle and heated at 75°C for 4 days. The reaction mixture was cooled to room temperature and pH was adjusted to 6.0/6.5 with dilute HCl. The aqueous solution was extracted with CH_2Cl_2 and the solvent was removed under reduced pressure. The resulting solid was recrystallized from 2-propanol to give compound (12) in 77% yield. ^{13}C NMR: (CDCl_3) δ ; 41.31 (NCH_3); 54.57 (CH_2N); 57.85 (CH_2C); 58.04 (OCH_3); 167.98 (CO).

EXAMPLE 11

A. SYNTHESIS OF COMPOUND (13)

mPEG sarcosine (12) (18 g, 3.55 mmol) was dissolved in anhydrous methylene chloride (90 ml) followed by the addition of N-hydroxysuccinimide (612 mg, 5.32 mmol) and diisopropyl carbodiimide (671 mg, 5.32 mmol). The mixture was stirred overnight at room temperature. The resulting solids were filtered and the solvent was removed in vacuo. The crude product was recrystallized from 2-propanol to give the compound (13) in 94% yield. ^{13}C NMR: (CDCl_3) δ ; 24.73 (CH_2 succinimide); 41.60 (N-CH_3); 54.57 (NCH_2); 54.44 (CH_2C); 58.11 (OCH_3); 165.13 (CO) 168.48 (C succinimide).

B. SYNTHESIS OF COMPOUND (14) BY CONJUGATION WITH COMPOUND (13) WITH BENZYLAMINE

Benzylamine (41.45 mg, 0.39 mmol) was added to Compound (13) (1 g, 0.19 mmol) in anhydrous CH_2Cl_2 (5 ml). The reaction mixture was kept at room

temperature overnight. The solvent was removed under reduced pressure and the residue was recrystallized from 2-propanol to give compound (14) in 80% yield. ^{13}C NMR: (CDCl_3) δ ; 41.94 (NCH_3); 42.65 (CH_2 Benzylamine); 56.32 (NCH_2); 58.12 (OCH_3); 60.22 (CH_2C); 126.32 to 137.99 (C Benzene ring); 169.70 (CO).

EXAMPLE 12

N-epsilon-Boc lysine (15), (0.246 g, 1 mmol) PEG 5,000-N-hydroxysuccinimide ester (16) (5 g, 1 mmol) are added to pH 8 borate buffer (30 ml). The mixture is stirred at room temperature for about 3 hours and then neutralized with dilute hydrochloric acid. The aqueous solution was extracted with dichloromethane (3 x 20 ml). The organic layer was dried (anhyd. Na_2SO_4) and evaporated under reduced pressure to yield 4.1 g, 79% N-epsilon-tert.-butoxycarbonyl-alpha PEGcarbamate of L-lysine (17)

EXAMPLE 13

N-epsilon-tert.-butoxycarbonyl-alpha PEGcarbamate of L-lysine (17) (5.2 g; 1.0 mmol) is dissolved in trifluoroacetic acid and dichloromethane (1:2, 30 ml) and left to stand at room temperature for one hour. The solution is evaporated to dryness in vacuo and the residue is triturated with dry ether, filtered, washed with ether and dried in vacuo to yield (3 g, 60%) of lysine-N-alpha-PEGcarbamate (18).

EXAMPLE 14

A mixture of lysine-N-alpha-PEGcarbamate (18) (5.1 g, 1 mmol) chloroethane sulfonic acid sodium salt (1.84 g, 10 mmol) in 20 ml of water is placed in a 10 ml polypropylene bottle. The bottle is sealed and kept in a water bath at 60°C for 48 hours followed by cooling to room temperature and removal of the solvent by distillation in vacuo. Recrystallization of the residue from 2-propanol yields (5.5 g, 80%) of the compound (19).

EXAMPLE 15

A solution of the compound (19) (5.2 g, 1 mmol) and N-hydroxysuccinimide (115 mg, 1 mmol) in dry dichloromethane is cooled in an ice water bath and diisopropylcarbodiimide (0.126 g, 1 mmol) is added with stirring. The mixture is kept

in a refrigerator overnight. The solvent is removed and the solid obtained is recrystallized from 2-propanol to give 4.3 g, (80%) of the product (19).

EXAMPLE 16

The following procedure details the conjugation of bovine hemoglobin (Hb), 9.8% solution, using an 18 fold molar excess of piperidine pI PEG (9) in the presence of 10% NaCl.

Piperidine pI PEG (9) 1.461 g, 2.842×10^{-4} M, is dissolved in 2 ml of pH 7.0 phosphate buffer (0.1 M) in a jacketed reaction vessel (0°C) and stirred for 10 minutes. Ten ml of the Hb solution is pipetted into another jacketed reaction vessel (8°C), along with 2.3 g NaCl. The pH is adjusted to 7.8. The pI PEG solution is added to the reaction vessel containing the Hb and the container is washed with 2 x 0.5 ml of the pH 7.0 buffer. The washings are then transferred to the Hb vessel. Seven ml of pH 7.8 phosphate buffer is added and the pH is adjusted to 7.8 with 1.0 N NaOH. The reaction mixture is stirred uniformly and slowly for about 2 hours at 8° C while maintaining the pH at 7.8.

After 2 hours, the reaction is quenched with cysteine HCl (0.105 g) and 124 µl of glycine solution (2.25×10^{-4} M). The pH is adjusted to 7.8 with 2 N NaOH. The conjugate can now be stored in the refrigerator between 4-6° C.

As will be readily appreciated, numerous variations and combinations of the features set forth above can be utilized without departing from the present invention as set forth in the claims. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and all such modifications are intended to be included within the scope of the following claims.

WHAT IS CLAIMED IS:

1. A substantially non-antigenic polymer comprising the formula:




wherein

(R) is a water-soluble, substantially non-antigenic polymer residue; and

(B) is a secondary amine or a tertiary amine.

2. The polymer of claim 1, wherein said secondary amine comprises the formula:




wherein

(n) is an integer from 1-12, inclusive; and


(X) is selected from the group consisting of H; OH; CO_2R_1 , where R_1 is H or a C_{1-6} alkyl; halogen; aryl moieties and heteroaromatic moieties.

3. The polymer of claim 1, wherein said tertiary amine comprises a formula selected from the group consisting of:




23

(V)



(VI)



wherein

(m) is an integer from 0-12, inclusive;

(X) is selected from the group consisting of H; OH; CO₂R₁, where R₁ is H or a C₁₋₆ alkyl; halogen, aryl moieties and heteroaromatic moieties;

(Y) is N or CH; and

(Z) is a C₁₋₆ alkyl.

4. The polymer of claim 1, wherein said polymer is a poly(alkylene oxide) residue.

5. The polymer of claim 4, wherein said poly(alkylene oxide) residue is capped with a C₁₋₄ alkyl group distal to said (B) moiety.

6. The polymer of claim 5, wherein said poly(alkylene oxide) residue is selected from the group consisting of poly(ethylene glycol) homopolymers, alkyl-capped poly(ethylene oxides), and copolymers of block copolymers of poly(alkylene oxides).


7. The polymer of claim 6, wherein said poly(alkylene oxide) has a molecular weight between about 200 and about 100,000.

8. The polymer of claim 7, wherein said poly(alkylene oxide) has a molecular weight between 1,000 and about 50,000.

9. The polymer of claim 8, wherein said poly(ethylene glycol) homopolymer has a molecular weight of from about 2,500 to about 25,000.

10. The polymer of claim 5, wherein (R) is a poly(ethylene glycol).

11. A substantially non-antigenic polymer comprising the formula:



wherein


(R) is a water-soluble, substantially non-antigenic polymer residue;

(B') is NY, wherein Y is H or a C₁₋₆ alkyl or cycloalkyl;

(W) is a spacer moiety; and

(L) is a functional group capable of bonding with nucleophiles.

12. The polymer of claim 11, wherein said secondary amine comprises the formula:




wherein:


(n) is an integer from 1-12, inclusive; and

(X) is selected from the group consisting of H; OH; CO₂R₁, where R₁ is H or a C₁₋₆ alkyl; halogen; aryl moieties and heteroaromatic moieties.


13. The polymer of claim 11, wherein said tertiary amine comprises a formula selected from the group consisting of:



(V)



(VI)



wherein

(m) is an integer from 0-12 inclusive;

(X) is selected from the group consisting of H; OH; CO₂R₁, where R₁ is H or a C₁₋₆ alkyl; halogen; aryl moieties and heteroaromatic moieties;

(Y) is N or CH; and

(Z) is a C₁₋₆ alkyl.

14. The polymer of claim 11, wherein said polymer is a poly(alkylene oxide) residue.

15. The polymer of claim 14, wherein said poly(alkylene oxide) residue is capped with a C₁₋₄ alkyl group distal to said (B') moiety.

16. The polymer of claim 14, wherein said poly(alkylene oxide) residue is selected from the group consisting of poly(ethylene glycol) homopolymers, alkyl-capped poly(ethylene oxides), and copolymers of block copolymers of poly(alkylene oxides).

17. The polymer of claim 16, wherein said poly(alkylene oxide) has a molecular weight between about 200 and about 100,000.

18. The polymer of claim 17, wherein said poly(alkylene oxide) has a molecular weight between 1,000 and about 50,000.

19. The polymer of claim 18, wherein said poly(ethylene glycol) homopolymer has a molecular weight of about 2,500 to about 25,000.

20. The polymer of claim 11, wherein (W) is a moiety selected from the group consisting of straight or branched C₁₋₄ alkyls, aralkyl, aryl and heteroaryl moieties.

21. The polymer of claim 20, wherein said moiety (W) is selected from the group consisting of ethyl-3-isocyanato propionate and ethyl-2-aminobutyrate.

22. The polymer of claim 11, wherein (L) is a moiety selected from the group consisting of:

functional groups capable of reacting with amino groups;


functional groups capable of reacting with carboxylic acid groups;

functional groups capable of reacting with reactive carbonyl groups; and

functional groups capable of reacting with mercapto groups.

23. The polymer of claim 22, wherein (L) is a succinimidyl or a p-nitrophenyl carbonate active ester.

24. A polymer conjugate comprising the formula:



wherein:

(R) is a water-soluble substantially non-antigenic polymer residue;

(B') is NY, wherein Y is H or a C₁₋₆ alkyl or cycloalkyl;

(W) is a spacer moiety;

(L¹) represents a covalent linkage between (R-B-W) and the nucleophile; and

(z) represents the number of polymers attached to the nucleophile.

25. The conjugate of claim 24, wherein R is a poly(alkylene oxide).

26. The conjugate of claim 25, wherein said poly(alkylene oxide) residue is capped with a C₁₋₄ alkyl group distal to said covalent linkage (L¹).

27. The conjugate of claim 26, wherein said poly(alkylene oxide) is selected from the group consisting of poly(ethylene glycol) homopolymers, alkyl-capped poly(ethylene oxides), and copolymers of block copolymers of poly(alkylene oxides).

28. The conjugate of claim 24, wherein said poly(alkylene oxide) has a molecular weight between about 200 and about 100,000.

29. The conjugate of claim 28, wherein said poly(alkylene oxide) has a molecular weight between 1,000 and about 50,000.

30. The conjugate of claim 29, wherein said poly(ethylene glycol) homopolymer has a molecular weight of about 2,500 and about 25,000.

31. The conjugate of claim 24, wherein R is a poly(ethylene glycol) homopolymer.

32. The conjugate of claim 24, wherein said nucleophile is selected from consisting of proteins, peptides, enzymes and polypeptides.

33. The conjugate of claim 32, wherein said enzyme is glucocerebrosidase.


34. The conjugate of claim 32, wherein said protein is selected from the group consisting of antibodies, monoclonal antibodies, fragments of antibodies and single chain-binding antigens.

35. The conjugate of claim 24, wherein said nucleophile is a member of the group consisting of anti-neoplastics, anti-infectives, anti-anxiety agents, anti-gastrointestinal agents, central nervous system-activating agents, analgesics, fertility, contraceptive agents, anti-inflammatory agents, steroidal agents, anti-urecemic agents, cardiovascular agents, vasodilating agents and vasoconstricting agents.

36. The conjugate of claim 35, wherein said antineoplastic agent is selected from the group consisting of taxol, taxanes, camptothecins, anthracyclines and methotrexates.

37. A method of treatment comprising administering to a mammal in need thereof a therapeutically effective amount of the polymer conjugate of claim 24.

FIG. 1



2/4

FIG. 2






FIG. 3



3/4



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/08909

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : 526/352; 514/772.3, 772.4, 772.6; 530/300, 313, 391.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 526/352; 514/772.3, 772.4, 772.6; 530/300, 313, 391.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS: NON-ANTIGENIC POLYMER, POLYETHYLENE GLYCOL, PEPTIDE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,690,916 (NESTOR, JR. ET AL.) 01 SEPTEMBER 1987, see entire document.	1-23
A	US, A, 4,481,190 (NESTOR ET AL.) 06 NOVEMBER 1984, see entire document.	1-23
Y	US, A, 4,179,337 (DAVIS ET AL.) 18 DECEMBER 1979, column 2, lines 43-66.	1-23

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"G" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

28 SEPTEMBER 1995

Date of mailing of the international search report

17 OCT 1995

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SHELLEY A. DODSON

Telephone No. (703) 308-1235

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-23

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 38/00, 47/30, 47/32, 47/42; C07K 16/00, 17/00, 17/14; C08F 110/02, 110/04; C12P 21/00, 21/08

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

- I. CLAIMS 1-23, DRAWN TO POLYMERS OF THE FORMULAE R-B OR R-B-L, CLASSIFIED IN CLASS 526, SUBCLASS 352.
- II. CLAIMS 24-36, DRAWN TO POLYMERS OF THE FORMULA R-B-L1 NUCLEOPHILE WHEREIN THE NUCLEOPHILE IS AN ANTIBODY, POLYPEPTIDE, OR PEPTIDE, CLASSIFIED IN CLASS 530, SUBCLASS 391.1 AND CLASS 514, SUBCLASS 772.4.
- III. CLAIM 37, DRAWN TO A METHOD OF TREATMENT USING THE COMPOUND OF CLAIM 24, CLASSIFIED IN CLASS 514, SUBCLASS 772.4.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The inventions have no special technical feature because the separate inventions do not represent a contribution over the prior art (see U.S. Patent 4,179,337). Accordingly, the claims of inventive group I are not linked by a special technical feature and do not provide a contribution over the prior art within the meaning of Rule 13.2 in view of the '337 patent.